SUPN Q2 2021 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SUPNSupernus Pharmaceuticals, Inc.

$3B

Q2 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$141M+11.5% YoY

Gross Profit

$116M82.3% margin

Operating Income

$34M24.1% margin

Net Income

$24M16.8% margin

EPS (Diluted)

$0.43

QoQ Revenue Growth

+7.9%

Cash Flow

Operating Cash Flow

$46M

Free Cash Flow

$46M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$1.6B

Total Liabilities

$787M

Stockholders' Equity

$786M

Cash & Equivalents

$224M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$141M	$127M	+11.5%
Gross Profit	$116M	$118M	-1.7%
Operating Income	$34M	$46M	-25.1%
Net Income	$24M	$35M	-31.6%

Revenue Segments

Product

$139M50%

Trokendi Xr

$79M28%

APOKYN

$27M10%

Oxtellar X R

$25M9%

MYOBLOC

$5M2%

XADAGO

$3M1%

Royalty

$3M1%

Qelbree

$315,0000%